Nephrotoxicity of immunosuppressive drugs: New insight and preventive strategies

Current Opinion in Critical Care

Volumn 7, Issue 6, 2001, Pages 384-389

  Olyaei, A J ^a   De Mattos, A M ^a   Bennett, W M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; ENDOTHELIN 1; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

AUTOIMMUNE DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MONITORING; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; NEPHROTOXICITY; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; RISK ASSESSMENT; VASOCONSTRICTION;

CALCINEURIN; CYCLOSPORINE; ENDOTHELIN-1; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; MYCOPHENOLIC ACID; NITRIC OXIDE; SIROLIMUS; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VASOCONSTRICTION;

EID: 0035659395     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200112000-00003     Document Type: Review

References (55)

1. Immunosuppressive medications for renal transplantation: A multiple choice question
2. A practical guide to the management of hypertension in renal transplant recipients
3. Immunosuppressant-induced nephropathy: Pathophysiology, incidence and management
4. Mechanisms of nephrotoxicity
5. Pharmacodynamics of immunosuppressive drugs
6. Nephrotoxicity of calcineurin inhibitors: New therapeutic approaches
7. A meta-analysis and morphologic review of cyclosporine-induced nephrotoxicity in auto-immune diseases
8. Cellular immunology markers postransplantation predictive of long-term graft outcome
9. Impact of acute rejection on development of chronic rejection in pediatric renal transplant recipients
10. The management of cyclosporine-induced nephrotoxicity after cardiac transplantation
11. The clinical impact of cyclosporine nephrotoxicity in heart transplantation
12. Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study
13. Kidney function in cyclosporine-treated paediatric pulmonary transplant recipients
14. Renal complications after heart transplantation
15. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study
16. The clinical impact of cyclosporine nephrotoxicity in heart transplantation
17. The clinical impact of nephrotoxicity in liver transplantation
18. The clinical impact of nephrotoxicity in renal transplantation
19. Cyclosporine-induced interstitial fibrosis and arteriolar TGF-beta expression with preserved renal blood flow
20. Mechanisms of nephrotoxicity
21. An animal model of chronic cyclosporine nephrotoxicity
22. The role of renal sympathetic nerves in experimental chronic cyclosporine nephropathy
23. The nephrotoxicity of new and old immunosuppressive drugs
24. Pharmacology of immunosuppressive medications used in renal diseases and transplantation
25. Acute cyclosporine A-induced nephrotoxicity: A rabbit model
26. A role for leukotrienes in cyclosporine nephrotoxicity
27. Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy
28. Role of intrarenal endothelin 1, endothelin 3, and angiotensin II expression in chronic cyclosporin A nephrotoxicity in rats
29. Cyclosporine induces different responses in human epithelial, endothelial and fibroblast cell cultures
30. Matrix accumulation in mesangial cells exposed to cyclosporine A requires a permissive genetic background
31. Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity
32. Nitric oxide mediates cyclosporine-induced apoptosis in cultured renal cells
33. Protective effects of dietary L-arginine supplementation on chronic cyclosporine nephrotoxicity
34. Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet
35. Effects of ACE inhibition on cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on a high-sodium diet
36. Can ACE inhibitors prevent chronic allograft failure?
37. Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat
38. Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates the in vivo effects of cyclosporine: Demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine
39. Perfenidone decreases TGF-β1 expression and ameliorates fibrosis in chronic cyclosporine nephrotoxicity
40. Sirolimus: A new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation
41. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
42. Sirolimus vs azathioprine
43. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations
44. Comparison of sirolimus and mycophenolate mofetil on renal function and morphology in post-ischemic rat kidney
45. Conversion to rapamycin immunosuppression in renal transplant recipients: Report of an initial experience
46. Conversion to sirolimus: How to determine the optimal window of opportunity. A single center experience
47. Sirolimus substitution for calcineurin-inhibitors in renal allograft recipients with calcineurin inhibitor nephrotoxicity
48. Rapamycin increase glomerular profibrotic gene expression after cyclosporine dose reduction in patients with chronic allograft nephropathy
49. Improved renal function with cyclosporine elimination in sirolimus-treated renal transplant recipients: One-year results from a phase II trial
50. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
51. The use of mycophenolate mofetil in transplant recipients
52. The evolving role of mycophenolate mofetil in renal transplantation
53. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection
54. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy
55. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction